Search

Labetalol

[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]

Potassium bitartrate

Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732 … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

Echinacea purpurea

Blonanserin

Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.

Betahistine

[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

Insulin icodec

[L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … Insulin icodec is an ultra long-acting basal insulin analogue.

Ferric maltol

[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [L10974] On December 22, 2025, the FDA expanded this indication to include pediatric patients aged 10 years and older. [L54873,L54878]

Esmolol

The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule

Revumenib

It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A.

Trazodone

[T646] It was initially granted FDA approval in 1981.[L3484]